MOG and myeloid sarcoma: However, when cell-based assays (CBAs) using cell lines expressing native proteins were subsequently developed to detect anti-MOG antibodies, they were able to more clearly distinguish MS patients (negative for MOG-IgG with nearly 100% specificity) from MOGAD patients (14, 15).